دورية أكاديمية
أعرض في EDS

Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome.

التفاصيل البيبلوغرافية
العنوان: Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome.
المؤلفون: Arora S; Internal Medicine, Government Medical College and Hospital, Chandigarh, Chandigarh, IND., Nair S; Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA., Prabhu R; Internal Medicine, Kasturba Medical College, Manipal, Manipal, IND., Avanthika C; Medicine and Surgery, Karnataka Institute of Medical Sciences, Hubli, IND.; Pediatrics, Karnataka Institute of Medical Sciences, Hubli, IND., Jhaveri S; Internal Medicine, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, IND., Samayam S; Internal Medicine, Government Medical College Siddipet, Siddipet, IND., Katta MR; Internal Medicine, Gandhi Medical College, Hyderabad, IND., Agarwal P; Internal Medicine, Bhaskar Medical College, Hyderabad, IND.
المصدر: Cureus [Cureus] 2021 Oct 24; Vol. 13 (10), pp. e19009. Date of Electronic Publication: 2021 Oct 24 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Antiphospholipid syndrome (APS) is an autoimmune disorder that causes venous, arterial and small-vessel thrombosis, pregnancy loss, and premature birth. Cardiac valvular disease, renal thrombotic microangiopathy, thrombocytopenia, hemolytic anemia, and cognitive impairment are some of its other clinical symptoms. Antiphospholipid antibodies cause endothelial cells, monocytes, and platelets to become activated, as well as an increase in tissue factor and thromboxane A2. Complement activation might play a key function in pathogenesis. Long-term oral anticoagulation is used to treat thrombosis, and individuals having arterial episodes should be treated quickly. Patients with systemic lupus erythematosus (SLE), as well as those with solely obstetric antiphospholipid syndrome, should get primary thromboprophylaxis. Obstetric care is based on a combination of medical and obstetric high-risk management, as well as aspirin and heparin therapy. Possible supplementary therapy for this condition is hydroxychloroquine. Statins, rituximab, and novel anticoagulant medicines are all potential future treatments for non-pregnant individuals with antiphospholipid syndrome. We aim to review the role of direct-acting oral anticoagulants (DOACs) as thromboprophylactic drugs in the treatment of APS in this article. The treatment of venous thromboembolism has been transformed by a new class of DOACs. These drugs, such as rivaroxaban, function by inhibiting factor Xa directly. Not only do they have known anticoagulant actions, but they also obviate the need for dosage monitoring and modification, in contrast to warfarin. We conducted an exhaustive literature search of PubMed/MEDLINE and Google Scholar Indexes using the keywords "Antiphospholipid syndrome," "thromboprophylaxis," and "oral anticoagulants" up to September 2021. We found that DOACs have been shown to be non-inferior to warfarin in a variety of anticoagulation situations in a number of high-powered clinical studies. In many hypercoagulable conditions such as APS, DOACs are quickly establishing themselves as first-line therapy. This article is focused on comprehensively reviewing the mechanism of action of DOACs, their role as thromboprophylactic drugs, risks and complications of DOACs, and comparing their efficacy with the standard treatment protocol and warfarin.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2021, Arora et al.)
References: J Thromb Haemost. 2018 May;16(5):842-848. (PMID: 29532628)
J Thromb Haemost. 2009 Oct;7(10):1737-40. (PMID: 19624461)
Blood Rev. 2017 Nov;31(6):406-417. (PMID: 28784423)
Blood Coagul Fibrinolysis. 2015 Jun;26(4):476-7. (PMID: 25923780)
Semin Thromb Hemost. 2008 Apr;34(3):236-50. (PMID: 18720303)
Vasc Med. 2016 Dec;21(6):506-514. (PMID: 27807306)
J Thromb Haemost. 2003 Jul;1(7):1504-14. (PMID: 12871286)
Chest. 2012 Feb;141(2 Suppl):e120S-e151S. (PMID: 22315258)
N Engl J Med. 2005 Sep 8;353(10):1028-40. (PMID: 16148288)
Ann Rheum Dis. 2015 Jun;74(6):1011-8. (PMID: 24464962)
Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):321-5. (PMID: 19228605)
J Rheumatol. 1989 May;16(5):623-5. (PMID: 2787862)
Postgrad Med. 2014 Nov;126(7):19-24. (PMID: 25387210)
Curr Rheumatol Rep. 2013 Jun;15(6):331. (PMID: 23649961)
Clin Med (Lond). 2011 Oct;11(5):467-9. (PMID: 22034708)
Expert Rev Hematol. 2017 Apr;10(4):365-374. (PMID: 28277850)
Ther Clin Risk Manag. 2015 Jun 24;11:967-77. (PMID: 26150723)
J Rheumatol. 2004 Aug;31(8):1560-7. (PMID: 15290736)
Arthritis Rheum. 2001 Dec;44(12):2870-8. (PMID: 11762948)
Lancet. 1999 Apr 24;353(9162):1431-6. (PMID: 10227240)
J Thromb Haemost. 2006 Feb;4(2):295-306. (PMID: 16420554)
Obstet Gynecol. 1995 Oct;86(4 Pt 1):555-9. (PMID: 7675379)
J Thromb Haemost. 2014 Sep;12(9):1428-36. (PMID: 24811969)
N Engl J Med. 2003 Sep 18;349(12):1133-8. (PMID: 13679527)
Fertil Steril. 1996 Oct;66(4):540-6. (PMID: 8816614)
J Immunol. 1994 Jan 15;152(2):653-9. (PMID: 7506730)
Am J Obstet Gynecol. 1999 May;180(5):1146-50. (PMID: 10329869)
Thromb Haemost. 2021 Mar;121(3):366-382. (PMID: 33160289)
J Thromb Haemost. 2004 Sep;2(9):1558-63. (PMID: 15333031)
Haemostasis. 1999;29(2-3):100-10. (PMID: 10629391)
J Clin Pharmacol. 2016 May;56(5):637-45. (PMID: 26358690)
Lancet. 1993 Aug 7;342(8867):341-4. (PMID: 8101587)
Thromb Res. 2014 Apr;133(4):671-81. (PMID: 24529498)
Lupus. 2011 Feb;20(2):206-18. (PMID: 21303837)
Clin Pharmacokinet. 2011 Oct;50(10):675-86. (PMID: 21895039)
J Autoimmun. 2000 Sep;15(2):145-51. (PMID: 10968901)
Am J Reprod Immunol. 2009 Aug;62(2):96-111. (PMID: 19614626)
Blood. 2018 Sep 27;132(13):1365-1371. (PMID: 30002145)
Br J Haematol. 2011 Aug;154(3):311-24. (PMID: 21671894)
Autoimmun Rev. 2006 Dec;6(2):81-4. (PMID: 17138248)
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101463. (PMID: 31866276)
Clin Pharmacokinet. 2009;48(1):1-22. (PMID: 19071881)
Arthritis Rheum. 2002 Apr;46(4):1019-27. (PMID: 11953980)
Thromb Res. 2015 Feb;135(2):388-93. (PMID: 25555316)
Blood. 2016 Mar 17;127(11):1417-25. (PMID: 26696010)
Clin Appl Thromb Hemost. 2018 Jan;24(1):192. (PMID: 28893087)
Autoimmunity. 2003 May;36(3):125-31. (PMID: 12911278)
Circulation. 2011 Jan 18;123(2):131-6. (PMID: 21200007)
Rheumatology (Oxford). 2018 Jul 1;57(7):1264-1270. (PMID: 29660074)
Blood. 2010 Mar 18;115(11):2292-9. (PMID: 19965621)
J Rheumatol. 2017 Aug;44(8):1165-1172. (PMID: 28572466)
Autoimmun Rev. 2010 Mar;9(5):A299-304. (PMID: 19932199)
Thromb Res. 2017 Mar;151 Suppl 1:S43-S47. (PMID: 28262233)
Curr Rheumatol Rep. 2011 Feb;13(1):77-80. (PMID: 20978875)
Eur J Vasc Endovasc Surg. 2014 Nov;48(5):487-8. (PMID: 25150440)
J Clin Invest. 1993 May;91(5):1877-83. (PMID: 8486759)
J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):554-62. (PMID: 25848131)
Curr Rheumatol Rep. 2001 Aug;3(4):271-6. (PMID: 11470044)
Arthritis Rheumatol. 2019 Sep;71(9):1545-1552. (PMID: 30957430)
West J Emerg Med. 2015 Jan;16(1):11-7. (PMID: 25671002)
Eur Heart J. 2013 Jul;34(27):2094-106. (PMID: 23625209)
Clin Pharmacokinet. 2013 Apr;52(4):243-54. (PMID: 23389892)
Am J Reprod Immunol. 1996 Aug;36(2):81-5. (PMID: 8862250)
Clin Immunol. 2019 Sep;206:53-62. (PMID: 29510235)
Autoimmun Rev. 2016 Dec;15(12):1120-1124. (PMID: 27639837)
J Thromb Haemost. 2018 Jun;16(6):1028-1039. (PMID: 29624847)
Europace. 2015 Apr;17(4):514-23. (PMID: 25694538)
Arthritis Rheum. 2013 Feb;65(2):464-71. (PMID: 23124321)
Lupus. 2015 Sep;24(10):1087-94. (PMID: 25940537)
Haematologica. 1993 Jan-Feb;78(1):1-4. (PMID: 8491417)
Thromb Haemost. 2002 Mar;87(3):518-22. (PMID: 11916085)
Ann Rheum Dis. 2019 Oct;78(10):1296-1304. (PMID: 31092409)
Autoimmun Rev. 2018 Oct;17(10):1011-1021. (PMID: 30103045)
Curr Med Res Opin. 2008 Oct;24(10):2757-65. (PMID: 18715524)
Semin Thromb Hemost. 2014 Mar;40(2):163-71. (PMID: 24500573)
Lupus. 2020 Oct;29(12):1571-1593. (PMID: 33100166)
Contraception. 2011 Aug;84(2):128-32. (PMID: 21757053)
Semin Thromb Hemost. 2015 Oct;41(7):788-801. (PMID: 26408923)
Arthritis Rheum. 2005 May;52(5):1545-54. (PMID: 15880836)
Obstet Gynecol. 1992 Oct;80(4):614-20. (PMID: 1407882)
Thromb Res. 2009 Jun;124(2):174-7. (PMID: 19101711)
Am J Obstet Gynecol. 1996 May;174(5):1584-9. (PMID: 9065133)
Br J Haematol. 2020 Apr;189(2):212-215. (PMID: 31943138)
Chest. 2012 Feb;141(2 Suppl):e691S-e736S. (PMID: 22315276)
J Thromb Haemost. 2015 Oct;13(10):1799-805. (PMID: 26270625)
BMJ. 1997 Jan 25;314(7076):253-7. (PMID: 9022487)
Ann Rheum Dis. 2005 Mar;64(3):462-7. (PMID: 15256379)
Lancet Haematol. 2016 Sep;3(9):e426-36. (PMID: 27570089)
Blood Adv. 2020 Oct 13;4(19):4693-4738. (PMID: 33007077)
Thromb Haemost. 2016 Jan;115(2):291-8. (PMID: 26403199)
N Engl J Med. 2016 Sep 22;375(12):1131-41. (PMID: 27573206)
Thromb Res. 2012 Feb;129(2):107-15. (PMID: 22014849)
Arthritis Rheum. 2008 Sep;58(9):2824-34. (PMID: 18759321)
N Engl J Med. 2011 Sep 8;365(10):883-91. (PMID: 21830957)
Arthritis Rheum. 2007 Jul;56(7):2382-91. (PMID: 17599766)
PLoS One. 2015 Sep 18;10(9):e0137444. (PMID: 26383245)
Clin Pharmacokinet. 2008;47(1):47-59. (PMID: 18076218)
Thromb Res. 2015 Jun;135(6):1191-7. (PMID: 25895847)
N Engl J Med. 1985 Jul 18;313(3):152-6. (PMID: 3925336)
J Thromb Haemost. 2005 Sep;3(9):2121-3. (PMID: 16102129)
Arthritis Care Res (Hoboken). 2013 Nov;65(11):1869-73. (PMID: 23861221)
Chest. 2012 Feb;141(2 Suppl):e152S-e184S. (PMID: 22315259)
N Engl J Med. 2015 Aug 6;373(6):511-20. (PMID: 26095746)
Expert Rev Cardiovasc Ther. 2011 Jul;9(7):841-4. (PMID: 21809964)
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002859. (PMID: 15846641)
Ann Intern Med. 2019 Nov 19;171(10):685-694. (PMID: 31610549)
Nat Rev Rheumatol. 2011 Jun;7(6):330-9. (PMID: 21556027)
فهرسة مساهمة: Keywords: antiphospholipid antibody (apla); direct acting oral anticoagulant; hypercoagulable state; rheumatology & autoimmune diseases; thromboprophylaxis; thrombosis
تواريخ الأحداث: Date Created: 20211126 Latest Revision: 20211127
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8610415
DOI: 10.7759/cureus.19009
PMID: 34824926
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.19009